Research programme: topical anti-TNF-alpha therapeutics - York PharmaAlternative Names: RPL-228
Latest Information Update: 04 Apr 2011
At a glance
- Originator York Pharma
- Class Small molecules
- Mechanism of Action Cytokine inhibitors; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 13 Jun 2007 Preclinical trials in Psoriasis in United Kingdom (Topical)